OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
Mediterranean Journal of Hematology and Infectious Diseases · 28.02.2026 · 18 (1) · e2026022
DOI: 10.4084/mjhid.2026.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 28.02.2026. Verfasst von Jon Salmanton-García und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicin…. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The therapeutic landscape of hematological malignancies has expanded rapidly, increasing survival but also exposing patients to pharmacokinetic variability and clinically relevant drug–drug interactions. Therapeutic drug monitoring (TDM) offers a pharmacokinetics-informed strategy to individualize dosing, yet its real-world implementation across drug classes and healthcare settings remains insufficiently characterized.
Methods
We conducted an international, cross-sectional online survey (December 2023–February 2024) assessing availability, utilization, and clinical impact of TDM in patients with hematological malignancies. Physicians from multiple specialties reported institutional practices, turnaround times, drug-specific monitoring strategies, and treatment modifications based on TDM results.
Results
A total of 209 physicians from 32 countries participated, predominantly from Europe (92%). TDM was widely accessible (97%), mainly performed onsite (79%), and perceived as beneficial by nearly all respondents (99%). Routine TDM was most frequently used for classical agents (methotrexate, cyclosporin A), antifungals, and antibiotics, but substantial interest was reported for targeted therapies, including BCL-2 inhibitors, BCR-ABL tyrosine kinase inhibitors, FLT3 inhibitors, and Bruton tyrosine kinase inhibitors. Treatment was modified based on TDM results by 71% of respondents, with faster turnaround times strongly associated with clinical action. Limited assay availability, delayed reporting, and insufficient clinical evidence were identified as key barriers to broader implementation.
Conclusions
TDM is widely available and actively influences clinical decision-making in the management of hematological malignancies. While firmly established for classical agents and anti-infectives, clinicians express growing interest in extending TDM to targeted therapies. Optimizing turnaround times, expanding assay availability, and integrating pharmacokinetics-informed dosing into clinical trials may further strengthen the role of TDM within precision medicine approaches in hematology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, and University Hospital Cologne, University of Cologne, Cologne, Ge…
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Faculty of Medicine, University of Cologne, University Hosp…
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
- Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine, University of Cologne, Cologne, Germany.
- Department of Science and Technology for Sustainable Development and One Health, Università Campus Bio-Medico di Roma and Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Zitieren
APA
Salmanton-García, J., Marchesi, F., Cornely, O. A., Stemler, J., & Menna, P. (2026). OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026022. https://doi.org/10.4084/mjhid.2026.022
Vancouver
Salmanton-García J, Marchesi F, Cornely OA, Stemler J, Menna P. OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026022. doi:10.4084/mjhid.2026.022
BibTeX
@article{SalmantonGarca2026,
author = {Salmanton-García, Jon and Marchesi, Francesco and Cornely, Oliver A and Stemler, Jannik and Menna, Pierantonio},
title = {OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES},
journal = {Mediterranean Journal of Hematology and Infectious Diseases},
year = {2026},
volume = {18},
number = {1},
pages = {e2026022},
doi = {10.4084/mjhid.2026.022}
}
EUVIMED